Running on mixed fuel‐dual agonistic approach of GLP‐1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non‐human primates

Jun 26, 2018Diabetes, obesity & metabolism

Activating both GLP-1 and glucagon receptors helps control body weight and blood sugar in mice and primates

AI simplified

Abstract

A higher loss in body weight was measured in dual agonist-treated obese mice compared to the selective GLP-1R agonist liraglutide.

  • Dual agonists significantly improved glycaemic control in both diet-induced obese mice and monkeys.
  • Increased total energy expenditure (TEE) and enhanced fat and carbohydrate oxidation were observed with the dual agonist, unlike liraglutide, which showed no effect on TEE.
  • Chronic treatment with the monkey-specific dual agonist reduced total energy intake to 60%-70% of baseline levels.
  • A decrease in body weight and significant improvement in glucose tolerance were noted in obese and diabetic monkeys.

AI simplified

Key numbers

21.1%
Body Weight Loss (Mice)
Weight loss percentage in dual agonist-treated mice compared to liraglutide.
8.2%
Body Weight Loss (Monkeys)
Weight loss percentage in monkeys treated with dual agonist.
60%-70%
Total Energy Intake Reduction
Reduction in total energy intake in monkeys during treatment.

Full Text

We can’t show the full text here under this license. Use the link below to read it at the source.

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free